Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity

References

• Bauer C, Osman AM, Cercignani G, Gialluca N, Paolini M (2001). A unified theory of enzyme kinetics based upon the systematic analysis of the variations of kcat, Km and kcat/Km and the relevant ΔGo values — possible implications in chemotherapy. Biochem Pharmacol 61:1049–55.
   PubMed Web of Science ®Google Scholar
• Chothia C, Lesk AM. (1986). The relation between the divergence of sequence and structure. EMBO J 5:823–6.
   PubMed Web of Science ®Google Scholar
• Coleman MD. (2005). Human drug metabolism: an introduction. Chichester: Wiley.
   Google Scholar
• De Groot MJ, Kirton SB, Sutcliffe MJ. (2004). In silico methods for predicting ligand binding determinants of cytochromes P450. Curr Topic Med Chem 4:1803–24.
   PubMed Web of Science ®Google Scholar
• De Groot MJ, Lewis DFV, Modi S (2006). Molecular modelling and quantitative structure–activity relationship (QSAR) of substrates and inhibitors of drug metabolism enzymes. In: Testa B, Van de Waterbeemd H, eds, Comprehensive medicinal chemistry II. Elsevier: Amsterdam, vol. 5, 809–25.
   Google Scholar
• Domanski TL, Halpert JR. (2001). Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Metab 2:117–37.
   PubMed Web of Science ®Google Scholar
• Ekroos M, Sjögren T (2006). Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 103:13682–7.
   PubMed Web of Science ®Google Scholar
• Furge LL, Guengerich FP. (2006). Cytochrome P450 enzymes in drug metabolism and chemical toxicology. Biochem Mol Biol Educ 34:66–74.
   PubMed Web of Science ®Google Scholar
• Gibson GG, Skett P (2001). Introduction to drug metabolism. Cheltenham: Nelson Thornes.
   Google Scholar
• Guengerich FP. (2005). Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed., Cytochrome P450. New York, NY: Kluwer/Plenum, 377–530.
   Google Scholar
• Guengerich FP. (2008). Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21:70–83.
   PubMed Web of Science ®Google Scholar
• Haines DC, Tomchick DR, Machius M, Peterson JA. (2001). Pivotal role of water in the mechanism of P450BM-3. Biochemistry 40:13456–65.
   PubMed Web of Science ®Google Scholar
• Hlavica P, Schulze J, Lewis DFV (2003). Functional interaction of cytochrome P450 with its redox partners: a critical assessment and update of the topology of predicted contact regions. J Inorg Biochem 96:279–97.
   PubMedGoogle Scholar
• Ioannides C, Lewis DFV (2004). Cytochrome P450 in the bioactivation of chemicals. Curr Topic Med Chem 4:1767–88.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kondo H, Goldfarb PS, Lewis DFV (2008). Analysis of CYP2D6 substrate interactions by computational methods. J Mol Graph Model 26:947–56.
   PubMed Web of Science ®Google Scholar
• Kleywegt GJ, Jones TA. (1994). Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallographica D 50:178–85.
   PubMed Web of Science ®Google Scholar
• Lesk AM, Chothia C (1986). The response of protein structures to amino-acid sequence changes. Phil Trans R Soc Lond A317:345–56.
   Google Scholar
• Lewis DFV (2000). Quantitative structure–activity relationships (QSARs) in substrates, inhibitors and inducers of mammalian cytochromes P450. Toxicology 144:197–203.
   PubMed Web of Science ®Google Scholar
• Lewis DFV (2001). Guide to cytochromes P450 structure and function. London: Taylor & Francis.
   Google Scholar
• Lewis DFV (2002a). Modelling human cytochromes P450 involved in drug metabolism from the CYP2C5 crystallographic template. J Inorg Biochem 91:502–14.
   PubMed Web of Science ®Google Scholar
• Lewis DFV (2002b). Molecular modelling of human P450–substrate interactions. Drug Metab Rev 34:55–67.
   PubMed Web of Science ®Google Scholar
• Lewis DFV (2002c). Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 32:305–23.
   PubMedGoogle Scholar
• Lewis DFV (2003a). Crystallographic and other structural models of the cytochrome P450cam (CYP101) catalytic cycle. Sci World 3:536–45.
   Google Scholar
• Lewis DFV (2003b). P450 structures and oxidative metabolism of xenobiotics. Pharmacogenomics 4:387–95.
   PubMed Web of Science ®Google Scholar
• Lewis DFV (2003c). Essential requirements for substrate binding and selectivity toward CYP2 family enzymes. Archiv Biochem Biophys 409:32–44.
   PubMed Web of Science ®Google Scholar
• Lewis DFV (2003d). P450 structures and oxidative metabolism of xenobiotics. Pharmacogenomics 4:387–95.
   PubMed Web of Science ®Google Scholar
• Lewis DFV (2003e). On the estimation of binding affinity (ΔGbind) for human P450 substrates (based on Km and KD values). Curr Drug Metab 4:331–40.
   PubMed Web of Science ®Google Scholar
• Lewis DFV (2003f). Human cytochromes P450 associated with the Phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr Med Chem 10:1955–72.
   PubMed Web of Science ®Google Scholar
• Lewis DFV (2004a). 57 varieties: the human cytochromes P450. Pharmacogenomics 5:305–18.
   PubMed Web of Science ®Google Scholar
• Lewis DFV (2004b). Quantitative structure–activity relationships (QSARs) within human cytochromes P450 substrates of the CYP2 family. Toxicol in Vitro 18:89–97.
   PubMed Web of Science ®Google Scholar
• Lewis DFV (2004c). Hydrogen bonding in human P450–substrate interactions: a major contribution to binding affinity. Sci World 4:1074–80.
   Google Scholar
• Lewis DFV, Broughton HB (2002). Molecular binding interactions: their estimation and rationalization in QSARs in terms of theoretically derived parameters. Sci World 2:1776–802.
   Google Scholar
• Lewis DFV, Dickins M (2002a). Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s. Toxicology 170:45–53.
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Dickins M (2002b). Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s. Toxicology 170:45–53.
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Dickins M (2002c). Human hepatic P450s: substrate characteristics and QSARs. Drug Disc Today 7:918–25.
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Dickins M (2002d). Substrate SARs in human P450s. Drug Disc Today 7:918–25.
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Dickins M (2003). Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism. Drug Metab Rev 35:1–18.
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Gillam EMJ, Everett S, Shimada T (2003). Molecular modelling of human CYP1B1 substrate interactions and investigation of allelic variant effects on metabolism. Chemico-Biol Interact 145:281–95.
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Ito Y (2008a). Cytochrome P450 structure and function — an evolutionary perspective. In: Ioannides C, ed., Cytochromes P450 — role in the metabolism and toxicity of drugs and other xenobiotics. Cambridge: Royal Society of Chemistry, 3–45.
   Google Scholar
• Lewis DFV, Ito Y (2008b). Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme–substrate interactions. Exp Opin Drug Metab Toxicol 4:1181–6.
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Ito Y, Goldfarb PS. (2006a). Cytochrome P450 structures and their substrate interactions. Drug Develop Res 66:19–24.
   Web of Science ®Google Scholar
• Lewis DFV, Ito Y, Goldfarb PS. (2006b). Structure and function of the cytochromes P450. Curr Med Chem 13:2645–52.
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Jacobs MJ, Dickins M (2004). Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Disc Today 9:530–7.
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Modi S, Dickins M (2002). Quantitative structure–activity relationships in substrates of human hepatic microsomal cytochromes P450. Drug Metab Rev 34:69–82.
   PubMed Web of Science ®Google Scholar
• Marques-Soares C, Dijols S, Macherey A-C, Wester MR, Johnson EF, Dansette PM, Mansuy D (2003). Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochrome P450 2C5: identification of a new high affinity substrate common to those enzymes. Biochemistry 42:6363–9.
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Horie T (2007). Toxicological significance of mechanism-based inactivation of cytochrome P450 enzymes by drugs. Crit Rev Toxicol 37:389–412.
   PubMed Web of Science ®Google Scholar
• Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Computat Chem 19:1639–62.
   Web of Science ®Google Scholar
• Morris GM, Goodsell DS, Huey R, Olson AJ. (1996). Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput-Aided Mol Des 10:293–304.
   PubMed Web of Science ®Google Scholar
• Rendic S (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:383–448.
   Google Scholar
• Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon CR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, Chenery RJ, Briggs AM. (2006). Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614–22.
   PubMed Web of Science ®Google Scholar
• Sansen S, Yano JK, Reynold RL, Schoch GA, Griffin KJ, Stout CD, Johnson EF. (2007). Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P4501A2. J Biol Chem 282: 14348–55.
   PubMed Web of Science ®Google Scholar
• Schlicting I, Berrendzen J, Chu K, Stock AM, Maves SA, Benson DE, Sweet RM, Ringe D, Petsko GA, Sligar SG. (2000). The catalytic pathway of cytochrome P450cam at atomic resolution. Science 287:1615–22.
   PubMedGoogle Scholar
• Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. (2004). Structure of human microsomal cytochrome P450 2C8. J Biol Chem 279:9497–503.
   PubMed Web of Science ®Google Scholar
• Scott EE, He YA, Wester MR, White MA, Chin CC, Halpert JR, Johnson EF, Stout CD. (2003). An open conformation of mammalian cytochrome P450 2B4 at 1.6å; resolution. Proc Natl Acad Sci USA 100:13196–201.
   PubMed Web of Science ®Google Scholar
• Scott EE, White MA, He YA, Johnson EF, Stout CD, Halpert JR. (2004). Structure of mammalian cytochrome P450 2B4, complexed with 4-(4-chlorophenyl)imidazole at 1.9å resolution. J Biol Chem 279:27293–301.
   Google Scholar
• Smith BD, Sanders JL, Porubsky PR, Lushington GH, Stout CD, Scott EE. (2007). Structure of the human lung cytochrome P450 2A13. J Biol Chem 282:17306–13.
   PubMed Web of Science ®Google Scholar
• Strushkevich N, Usanov SA, Plotnikov AN, Jones G, Park H-W. (2008). Structural analysis of CYP2R1 in complex vitamin D3. J Mol Biol 380:95–106.
   PubMed Web of Science ®Google Scholar
• Wester MR, Johnson EF, Marques-Soares C, Dansette PM, Mansuy D, Stout CD. (2003a). Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3å resolution: evidence for multiple substrate binding modes. Biochemistry 42:6370–9.
   PubMed Web of Science ®Google Scholar
• Wester MR, Johnson EF, Marques-Soares C, Dijols S, Dansette PM, Mansuy D, Stout CD. (2003b). Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1å resolution: evidence for an induced fit model of substrate binding. Biochemistry 42:9335–45.
   PubMed Web of Science ®Google Scholar
• Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, Johnson EF. (2004). The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0å resolution. J Biol Chem 279:35630–7.
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE. (2000). Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5:121–31.
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, Jhoti H (2004). Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683–6.
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Ward A, Angove HC, Vinkovic DM, Jhoti H (2003). Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464–8.
   PubMed Web of Science ®Google Scholar
• Yano JK, Hsu M-H, Griffin KJ, Stout CD, Johnson EF. (2005). Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struc Mol Biol 12:822–3.
   PubMed Web of Science ®Google Scholar
• Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. (2004). The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2,05å resolution. J Biol Chem 279:38091–4.
   PubMed Web of Science ®Google Scholar
• Zhang Q-Y, Ding X (2008). The CYP2F, CYP2G and CYP2J subfamilies. In: Ioannides C, ed., Cytochromes P450 — role in the metabolism and toxicity of drugs and other xenobiotics. Cambridge: Royal Society of Chemistry, 309–53.
   Google Scholar
• Zhao Y, White MA, Muralidhara BK, Sun L, Halpert JR, Stout CD. (2006). Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole. J Biol Chem 281:5973–81.
   PubMed Web of Science ®Google Scholar